Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

about

Year in review 2008: Critical Care--nephrology

P2860

Q33386829-B98ED18B-59BD-4CF1-82C9-ABC40528ACDE

P2860

Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

Item

http://www.wikidata.org/entity/Q41910010

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Does tirofiban prevent platele ...... ous renal replacement therapy?

@en

type

Item

label

Does tirofiban prevent platele ...... ous renal replacement therapy?

@en

prefLabel

Does tirofiban prevent platele ...... ous renal replacement therapy?

@en

P1476

Does tirofiban prevent platele ...... ous renal replacement therapy?

@en

P2093

Achim Jörres

http://www.w3.org/2001/XMLSchema#string

Christian Storm

http://www.w3.org/2001/XMLSchema#string

P2860

Variable extent of clopidogrel responsiveness in patients after coronary stenting

A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.

In vitro norepinephrine significantly activates isolated platelets from healthy volunteers and critically ill patients following severe traumatic brain injury

Tirofiban preserves platelet loss during continuous renal replacement therapy in a randomised prospective open-blinded pilot study

Renal replacement strategies in the ICU.

Pharmacologic platelet anesthesia by glycoprotein IIb/IIIa complex antagonist and argatroban during in vitro extracorporeal circulation.

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.

Platelet anaesthesia during extracorporeal circulation: differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia.

Acute renal failure in patients with severe sepsis and septic shock--a significant independent risk factor for mortality: results from the German Prevalence Study.

P2888

cc7083

P304

193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/CC7083

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23553742

http://www.w3.org/2001/XMLSchema#string

P6179

1018234557

http://www.w3.org/2001/XMLSchema#string

P698

19040776

http://www.w3.org/2001/XMLSchema#string

P921

cardiogenic shock

P932

2646330

http://www.w3.org/2001/XMLSchema#string

Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

about

P2860

P2860

Does tirofiban prevent platelet loss in patients after cardiogenic shock during continuous renal replacement therapy?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P921

P932